Expanding Research Portfolio SciSparc and its subsidiaries are actively developing innovative therapies targeting major health issues such as obesity, fatty liver disease, and CNS disorders, presenting opportunities to collaborate with healthcare providers, pharmaceutical companies, and research organizations focused on metabolic and neurological treatments.

Strategic Technology Acquisition The recent acquisition of a majority stake in CliniQuantum, a quantum technology firm, indicates potential for integrating advanced quantum computing solutions into clinical trials, offering a unique selling proposition to biotech and pharma companies looking to accelerate drug development and precision medicine.

Growth in Biotech Collaborations Partnerships with Clearmind Medicine and NeuroThera Labs demonstrate a strong focus on developing non-hallucinogenic therapeutics for mental health and metabolic conditions, providing sales prospects with organizations interested in alternative, safer treatment options for large patient populations.

Market Opportunity in CNS and Metabolic Disorders With therapies targeting depression, weight loss, and fatty liver disease under patent application, the company is positioned to tap into a rapidly growing global market projected to exceed $200 billion, ideal for engaging providers, clinics, and health tech platforms aligned with these therapeutic areas.

Financial Strength and Market Presence Generating revenues between $25 million and $50 million, SciSparc and its subsidiaries are financially positioned to invest in key partnership opportunities, facilitating outreach to industry stakeholders seeking innovative biotech solutions with proven revenue streams.